TJ-L1C4

**TJ-L1C4** is an investigational **bispecific monoclonal antibody** developed by **I-Mab** for oncology. It is designed to simultaneously target **programmed death-ligand 1** and **cluster of differentiation 47**, combining checkpoint blockade of the PD-L1 axis with inhibition of the CD47-SIRPalpha innate immune evasion pathway. The program has been described as part of I-Mab's PD-L1-based bispecific antibody portfolio for treatment of **solid tumors** and broader **neoplasms**. Publicly available pipeline sources indicate the asset remained **preclinical** and has also been described in some commercial databases as **discontinued**, so its current development fate appears uncertain from the available evidence.